Subject characteristics
| . | . | n (%) . |
|---|---|---|
| Sex | ||
| | Male | 49 (71.0%) |
| | Female | 20 (29.0%) |
| Age | ||
| | Median | 9 years |
| | Range | 6–16 years |
| Race/ethnicity | ||
| | American Indian/Alaska native (non-Hispanic) | 4 (6.45%) |
| | Asian/Pacific Islander | 9 (14.52%) |
| | Black | 3 (4.84%) |
| | Hispanic (any race) | 19 (30.65%) |
| | White/non-Hispanic | 27 (43.55%) |
| | Unknown | 7 (6.4%) |
| Mutation | ||
| | DCLRE1C | 4 (5.8%) |
| | IL2RG/or JAK3 | 34 (49.3%) |
| | IL7R/or CD3D | 10 (14.5%) |
| | RAG1/2 | 11 (15.9%) |
| | Unknown | 10 (14.5%) |
| Trigger for diagnosis | ||
| | FH | 12 (17.4%) |
| | Infection/or clinical symptoms | 24 (34.8%) |
| | NBS | 33 (47.8%) |
| Donor type | ||
| | Autologous (GT) | 3 (4.4%) |
| | HLA matched sibling | 4 (5.8%) |
| | HLA matched unrelated/other non-sibling relative | 25 (36.2%) |
| | HLA mismatched relative | 23 (33.3%) |
| | HLA mismatched unrelated | 14 (20.3%) |
| Type of conditioning | ||
| | None/immunosuppressive therapy alone | 38 (55.1%) |
| | Reduced intensity/myeloablative | 31 (44.9%) |
| . | . | n (%) . |
|---|---|---|
| Sex | ||
| | Male | 49 (71.0%) |
| | Female | 20 (29.0%) |
| Age | ||
| | Median | 9 years |
| | Range | 6–16 years |
| Race/ethnicity | ||
| | American Indian/Alaska native (non-Hispanic) | 4 (6.45%) |
| | Asian/Pacific Islander | 9 (14.52%) |
| | Black | 3 (4.84%) |
| | Hispanic (any race) | 19 (30.65%) |
| | White/non-Hispanic | 27 (43.55%) |
| | Unknown | 7 (6.4%) |
| Mutation | ||
| | DCLRE1C | 4 (5.8%) |
| | IL2RG/or JAK3 | 34 (49.3%) |
| | IL7R/or CD3D | 10 (14.5%) |
| | RAG1/2 | 11 (15.9%) |
| | Unknown | 10 (14.5%) |
| Trigger for diagnosis | ||
| | FH | 12 (17.4%) |
| | Infection/or clinical symptoms | 24 (34.8%) |
| | NBS | 33 (47.8%) |
| Donor type | ||
| | Autologous (GT) | 3 (4.4%) |
| | HLA matched sibling | 4 (5.8%) |
| | HLA matched unrelated/other non-sibling relative | 25 (36.2%) |
| | HLA mismatched relative | 23 (33.3%) |
| | HLA mismatched unrelated | 14 (20.3%) |
| Type of conditioning | ||
| | None/immunosuppressive therapy alone | 38 (55.1%) |
| | Reduced intensity/myeloablative | 31 (44.9%) |